Alaunos Therapeutics is an oncology-focused cell therapy company developing adoptive T-cell receptor (TCR) therapies, designed to treat various solid tumor types in cancer patient. Co. is utilizing its cancer mutation hotspot TCR library and its proprietary, non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from tumor-related mutations in main oncogenic genes, including KRAS, TP53 and EGFR. Co. evaluates TCRs reactive to mutated KRAS, TP53 and EGFR from its TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers. The TCRT stock yearly return is shown above.
The yearly return on the TCRT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TCRT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|